merck.com
Investor relations
Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.
NYSE: MRK
August 6, 2021 12:42 am ET
Delayed at least 20 minutes
View stock information
$75.59
+ 0.11 (+0.15%)
Latest news, events & financials

August 5, 2021
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
July 29, 2021
Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
July 29, 2021
Merck Announces Second-Quarter 2021 Financial Results
View all
Merck & Co., Inc. Q2 2021 Earnings Call
Dial: (833) 353-0277 or (469) 886-1947
Access Code: 5951886
Webcast
2Q21 Merck Earnings Presentation
2Q21 Merck Earnings Announcement
2Q21 Merck Other Financial Disclosures
Transcript
See full agenda
Our pipeline shows our relentless pursuit of the next breakthrough.
Explore our pipeline
Phase II programs
38
Phase III programs
22
Under review
5
Our leadership
Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.
Leadership
Corporate responsibility
Supporting the future of our business and the health and well-being of patients, people and communities around the world.
Explore our CR report
Download ESG Progress Report
We're led by our science
We follow the science to our next breakthrough, leaving no stone unturned.
View our stories
Innovation
Our second-quarter 2021 financial results
Merck announced second-quarter 2021 sales from continuing operations (excluding Organon) of $11.4 billion, 22% above second-quarter 2020. Excluding the impact from foreign exchange, sales grew 19%. The company anticipates full-year 2021 revenue range to be between $46.4 billion and $47.4 billion, including a positive impact from foreign exchange of less than 2%. Take a look […]
Read more
Sign up for email alerts
Receive company news, updates and other information
Unsubscribe from email alerts
For questions, please contact our team.
Contact investor relations
(908) 740 – 1468
investor_relations@merck.com
Related links
About our company
Discover how we invent for life
Financial information
Find information about our quarterly reports, annual reports & proxy and SEC filings
Stock information
See stock quotes and charts on a monthly, quarterly or yearly basis
Connect with us on social
For patients and health care professionals
MerckHelps
Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients
Merck Access Program
Information about insurance coverage and financial assistance options for eligible patients
Clinical trials
Learn about our clinical trials and find available studies
Merck Manuals
Medical information source covering thousands of topics in all fields of medicine
Corporate responsibility
Corporate Responsibility Report
Reporting on our commitment to society, people and communities around the world
Merck for Mothers
An initiative to create a world where no woman has to die giving life
About Merck
Merck Animal Health
The global animal health business unit of Merck
Forward-looking statement
Cookie policy
Cookie Preferences
Privacy
Transparency disclosure
Terms of use Sitemap
Copyright © 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
This Site Uses Cookies and Your Privacy Choice Is Important to Us
We suggest you choose Customize My Settings to make your individualized choices. Accept All Cookies means that you are choosing to accept third-party Cookies and that you understand this choice. See our Privacy Policy
Merck.com